TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32154021

Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Higher dose doxorubicin (375-600 mg/m2)
Number of subjects: 0
Study: 32154325

Group type: EXPERIMENTAL
Intervention: IMI/REL
Number of subjects: 47

Group type: COMPARATOR
Intervention: Colistin plus IMI
Number of subjects: 47
Study: 32154359

Group type: EXPERIMENTAL
Intervention: Immediate coronary angiography
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 78
Study: 32154361

Group type: EXPERIMENTAL
Intervention: Caycedian Sophrology (8 group sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study: 32154430

Group type: EXPERIMENTAL
Intervention: Intensive AN/BQ cessation program (22-day cessation program modeled after a smoking cessation program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational booklet and cessation program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational booklet
Number of subjects: 0
Study: 32154497

Group type: EXPERIMENTAL
Intervention: ULT (Iron-Enriched Supplement)
Number of subjects: 0
Study: 32154499

Group type: EXPERIMENTAL
Intervention: Human milk-based fortifier (HMBF)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Bovine milk-based fortifier (BMBF)
Number of subjects: 127

Group type: COMPARATOR
Intervention: HMBF and BMBF
Number of subjects: 127
Study: 32154962

Group type: EXPERIMENTAL
Intervention: ENMD-2076
Number of subjects: 35
Study: 32155200

Group type: EXPERIMENTAL
Intervention: Combined antiretroviral therapy (cART)
Number of subjects: 56

Group type: COMPARATOR
Intervention: HIV-uninfected controls (HUCs)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cerebral small-vessel diseases (CSVD) in PLHIVs
Number of subjects: 56

Group type: COMPARATOR
Intervention: Cerebral small-vessel diseases (CSVD) in HUCs
Number of subjects: 56
Study: 32156491

Group type: EXPERIMENTAL
Intervention: Decipher genomic classifier (GC) scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAM50 molecular subtypes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age decile
Number of subjects: 0
Study: 32156630

Group type: EXPERIMENTAL
Intervention: IXIARO® Japanese encephalitis vaccine (2-dose primary series)
Number of subjects: 23
Study: 32156743

Group type: EXPERIMENTAL
Intervention: Tirabrutinib monotherapy (80 mg every day)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Tirabrutinib in combination with Idelalisib (50 mg twice a day or 100 mg every day)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Tirabrutinib in combination with Entospletinib (200 mg or 400 mg every day)
Number of subjects: 53
Study: 32157282

Group type: EXPERIMENTAL
Intervention: Maternal nonsecretors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maternal secretors
Number of subjects: 0
Study: 32157590

Group type: EXPERIMENTAL
Intervention: Telotristat ethyl treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard of care (somatostatin analogues)
Number of subjects: 44
Study: 32158204

Group type: EXPERIMENTAL
Intervention: Annual AIx measurement by applanation tonometry
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Change in diffusion capacity (DLco)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein (LDL)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: High-sensitivity c-reactive protein (hsCRP)
Number of subjects: 76
Study: 32158272

Group type: EXPERIMENTAL
Intervention: Low dose aspirin and statins offered to men with AAA after the millennium (VIVA and DANCAVAS trials)
Number of subjects: 34079
Study: 32158386

Group type: EXPERIMENTAL
Intervention: Multiple-modality exercise with mind-motor training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control group (M2)
Number of subjects: 0
Study: 32158432

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32159070

Group type: EXPERIMENTAL
Intervention: Low-Fat Diet Intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased plant protein (upper quartile, increased total protein by ≥3.3% of energy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decreased total protein (lower quartile, decreased total protein ≥0.6% of energy)
Number of subjects: 0
Study: 32160020

Group type: EXPERIMENTAL
Intervention: ClinGen criteria modifications applied to variants
Number of subjects: 97
Study: 32160294

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (5 mg twice daily plus corticosteroids)
Number of subjects: 71
Study: 32160304

Group type: EXPERIMENTAL
Intervention: rs5780218
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: rs708910
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: rs932491
Number of subjects: 314
Study: 32160378

Group type: EXPERIMENTAL
Intervention: Sleep bruxism
Number of subjects: 146
Study: 32160856

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration using micro-Computed Tomography (micro-CT)
Number of subjects: 87
Study: 32161065

Group type: EXPERIMENTAL
Intervention: Modem technology for remote monitoring in domiciliary NIV
Number of subjects: 34
Study: 32161368

Group type: EXPERIMENTAL
Intervention: Xentuzumab 1000 mg weekly (part II of study 1280.1 and 1280.2)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Xentuzumab (various doses from 10-1800 mg weekly in study 1280.1 and 10-3600 mg three-weekly in study 1280.2)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Xentuzumab 1000 mg weekly
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Xentuzumab
Number of subjects: 125
Study: 32161547

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 62
Study: 32161584

Group type: EXPERIMENTAL
Intervention: Adjuvant ipilimumab co-administration with a peptide vaccine
Number of subjects: 0
Study: 32161660

Group type: EXPERIMENTAL
Intervention: KAPA intervention (six group sessions of motivational interviewing, monthly)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 32161659

Group type: EXPERIMENTAL
Intervention: HSP70-exosomes detection in blood
Number of subjects: 80
Study: 32161773

Group type: EXPERIMENTAL
Intervention: SS-OCT in emmetropic eyes
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: SS-OCT in mild/moderate myopic eyes
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: SS-OCT in high myopic eyes
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Correlation of tilt with axial length
Number of subjects: 279
Study: 32161846

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) infusions, initially every 4 weeks, then extended to every 6 weeks for the first 3 months, with subsequent intervals determined by the clinician
Number of subjects: 13
Study: 32162412

Group type: EXPERIMENTAL
Intervention: Exclusively breastfed infants (EBF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Partially breastfed infants (PBF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mothers' breast milk iodine concentration (BMIC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Estimated iodine intake from urinary data
Number of subjects: 60
Study: 32162723

Group type: EXPERIMENTAL
Intervention: Escitalopram (SCIT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: S-desmethylcitalopram (SDCIT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Escitalopram (SCIT) and S-desmethylcitalopram (SDCIT)
Number of subjects: 33
Study: 32162826

Group type: EXPERIMENTAL
Intervention: Married or partnered patients
Number of subjects: 367

Group type: COMPARATOR
Intervention: Single patients
Number of subjects: 367
Study: 32163181

Group type: EXPERIMENTAL
Intervention: Transarterial Embolisation (TAE)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolisation (TACE)
Number of subjects: 61

Group type: COMPARATOR
Intervention: No active therapeutic intervention (Control)
Number of subjects: 61
Study: 32163420

Group type: EXPERIMENTAL
Intervention: Chikungunya infection (acute phase)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Headache
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Vertigo
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Vomiting
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Dyspnea
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Intravenous rehydration
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Urea levels
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Enthesitis
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Tenosynovitis
Number of subjects: 193
Study: 32163431

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Text Messaging Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32163613

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneously every 6 months)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Historical controls (not treated with denosumab)
Number of subjects: 15
Study: 32163631

Group type: EXPERIMENTAL
Intervention: RAPP-children
Number of subjects: 150
Study: 32163639

Group type: EXPERIMENTAL
Intervention: Strong desire to void (SDV)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Post-void (PV)
Number of subjects: 30
Study: 32163675

Group type: EXPERIMENTAL
Intervention: Successful revascularization (TIMI Flow 3 post-PCI)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: One-vessel disease
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Multivessel disease
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Arrhythmic complications during PCI
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Median symptom-to-balloon time
Number of subjects: 158
Study: 32164435

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion during exercise testing
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Exercise testing with isoproterenol
Number of subjects: 13
Study: 32164542

Group type: EXPERIMENTAL
Intervention: Functional home care model with a highly trained team designed for preventive home interventions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional integrated home care model.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional home care model with a highly trained team.
Number of subjects: 0
Study: 32164567

Group type: EXPERIMENTAL
Intervention: ENDING-S
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: SOFA
Number of subjects: 220
Study: 32164580

Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale (CFS) assessment
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: CFS
Number of subjects: 294
Study: 32164626

Group type: EXPERIMENTAL
Intervention: High homologous recombination deficiency (HRD)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tumor mutation burden (TMB)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High HRD score
Number of subjects: 19
Study: 32164691

Group type: EXPERIMENTAL
Intervention: Feel4Diabetes-intervention
Number of subjects: 45
Study: 32164690

Group type: EXPERIMENTAL
Intervention: Feel4Diabetes intervention
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Screening questionnaires (FINDRISC) and blood glucose measurement
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intervention intensity
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Participants < 45 years
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Complementary review
Number of subjects: 27
Study: 32164704

Group type: EXPERIMENTAL
Intervention: Free vitamin D
Number of subjects: 90

Group type: COMPARATOR
Intervention: Total serum vitamin D
Number of subjects: 90
Study: 32164707

Group type: EXPERIMENTAL
Intervention: Informative booklet about palliative care issues
Number of subjects: 38
Study: 32164760

Group type: EXPERIMENTAL
Intervention: Haploidentical donor (HID) transplant
Number of subjects: 278

Group type: COMPARATOR
Intervention: HLA-matched sibling donor (MSD) transplant
Number of subjects: 278
Study: 32164884

Group type: EXPERIMENTAL
Intervention: POC-hs-cTnI-TriageTrue
Number of subjects: 1261

Group type: COMPARATOR
Intervention: hs-cTnT-Elecsys
Number of subjects: 1261

Group type: COMPARATOR
Intervention: hs-cTnI-Architect
Number of subjects: 1261

Group type: EXPERIMENTAL
Intervention: 0/1-h algorithm
Number of subjects: 1261

Group type: EXPERIMENTAL
Intervention: Ruled-out patients
Number of subjects: 1261
Study: 32164898

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32164981

Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with cytotoxic chemotherapy (4 cycles)
Number of subjects: 72
Study: 32165033

Group type: EXPERIMENTAL
Intervention: Rett Syndrome Behavioural Questionnaire
Number of subjects: 149
Study: 32165065

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab
Number of subjects: 84

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 84
Study: 32165096

Group type: EXPERIMENTAL
Intervention: FOLFOX-based therapy
Number of subjects: 1532

Group type: EXPERIMENTAL
Intervention: TIL density
Number of subjects: 1532

Group type: EXPERIMENTAL
Intervention: Tumor budding
Number of subjects: 1532

Group type: EXPERIMENTAL
Intervention: Combined variable of TIL density and tumor budding
Number of subjects: 1532
Study: 32165181

Group type: EXPERIMENTAL
Intervention: WiSE-CRT system
Number of subjects: 90
Study: 32165240

Group type: EXPERIMENTAL
Intervention: Weight loss (>5% over 8 weeks)
Number of subjects: 117
Study: 32166305

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral treatment for HCV
Number of subjects: 177
Study: 32166491

Group type: EXPERIMENTAL
Intervention: Neural network
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random Forest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Logistic regression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lung-RADS classification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Binary visual analysis
Number of subjects: 0
Study: 32166621

Group type: EXPERIMENTAL
Intervention: Opioids prescribed at discharge
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Unused opioids at follow-up
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Storage of opioids in the home
Number of subjects: 110
Study: 32167657

Group type: EXPERIMENTAL
Intervention: Exergame (Nintendo Wii)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Motivational support (control)
Number of subjects: 605
Study: 32167803

Group type: EXPERIMENTAL
Intervention: Self-efficacy interventions, specific details not available
Number of subjects: 0
Study: 32167861

Group type: EXPERIMENTAL
Intervention: Bemarituzumab (FPA144) at doses of 0.3 to 15 mg/kg every 2 weeks
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Bemarituzumab (FPA144) at doses of ≥ 10 mg/kg every 2 weeks for ≥ 70 days
Number of subjects: 79
Study: 32168157

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 10
Study: 32168159

Group type: EXPERIMENTAL
Intervention: CONVENTIONAL
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: FAST
Number of subjects: 7
Study: 32168224

Group type: EXPERIMENTAL
Intervention: HCV antibody positive women (case group)
Number of subjects: 131

Group type: COMPARATOR
Intervention: HCV antibody negative women (control group)
Number of subjects: 131
Study: 32168240

Group type: EXPERIMENTAL
Intervention: Silicone-hydrogel daily disposable contact lenses (delefilcon A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hydrogel daily disposable contact lenses (omafilcon A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Initially symptomatic subjects (OSDI ≥13)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Initially asymptomatic subjects (OSDI <13)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Baseline vs. post-study visits for OSDI
Number of subjects: 50

Group type: COMPARATOR
Intervention: Baseline vs. 12-month visit for OSDI
Number of subjects: 50

Group type: COMPARATOR
Intervention: Baseline vs. 12-month visit for Contact Lens Dry Eye Questionnaire
Number of subjects: 50
Study: 32168980

Group type: EXPERIMENTAL
Intervention: Aflibercept + FOLFIRI (fluorouracil, leucovorin, and irinotecan)
Number of subjects: 766
Study: 32169050

Group type: EXPERIMENTAL
Intervention: Frailty assessment using Fried's frailty phenotype
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Baroreflex function assessment
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Orthostatic decrements of BP to HUT-60°
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Self-reported dizziness symptoms
Number of subjects: 93
Study: 32169255

Group type: EXPERIMENTAL
Intervention: Preoperative performance on the Trail Making Test
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Preoperative performance on the Stroop test
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Colour-word matching Stroop test performance
Number of subjects: 300
Study: 32169783

Group type: EXPERIMENTAL
Intervention: Durvalumab (Du) 1500 mg every 3 weeks (q3w)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Tremelimumab (Tr) 75 mg q3w for 5 doses
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Combination of Du and Tr with platinum-doublet chemotherapy
Number of subjects: 136

Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed, gemcitabine, etoposide, nab-paclitaxel with cisplatin or carboplatin)
Number of subjects: 136
Study: 32169872

Group type: EXPERIMENTAL
Intervention: hu14.18K322A mAb treatment
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: PATA+ status
Number of subjects: 38
Study: 32169927

Group type: EXPERIMENTAL
Intervention: Symphysis-fundal height (SFH) measurement
Number of subjects: 1486

Group type: EXPERIMENTAL
Intervention: SFH <26 cm for GA <28 weeks
Number of subjects: 1486

Group type: EXPERIMENTAL
Intervention: SFH <29 cm for GA <34 weeks
Number of subjects: 1486

Group type: EXPERIMENTAL
Intervention: Estimated uterine volume (EUV)
Number of subjects: 1486

Group type: EXPERIMENTAL
Intervention: Best model without including last menstrual period
Number of subjects: 1486
Study: 32169933

Group type: EXPERIMENTAL
Intervention: Accelerometer (AG)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Fitbit (FB)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Both devices (AG and FB)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Spanish-language pictograms
Number of subjects: 88
Study: 32170554

Group type: EXPERIMENTAL
Intervention: Gefitinib plus chemotherapy (pemetrexed plus carboplatin)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Gefitinib alone
Number of subjects: 81
Study: 32170905

Group type: EXPERIMENTAL
Intervention: FFR-guided revascularization
Number of subjects: 2217
Study: 32171061

Group type: EXPERIMENTAL
Intervention: MOR202 monotherapy (0.01 mg/kg to 16 mg/kg)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: MOR202 with dexamethasone
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: MOR202 with dexamethasone plus pomalidomide
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: MOR202 with dexamethasone plus lenalidomide
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: MOR202 (all groups)
Number of subjects: 91
Study: 32171069

Group type: EXPERIMENTAL
Intervention: Venetoclax (360 mg/m) in combination with chemotherapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Venetoclax (240 mg/m) during dose escalation
Number of subjects: 38
Study: 32171104

Group type: EXPERIMENTAL
Intervention: S-1 (80-120 mg/day on days 1-14) and oxaliplatin (130 mg/m2) followed by surgery
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: S-1 and oxaliplatin followed by surgery
Number of subjects: 29
Study: 32171470

Group type: EXPERIMENTAL
Intervention: Androgen-deprivation therapies (ADTs)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Enzalutamide (25μM)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone (30nM)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Enzalutamide
Number of subjects: 184
Study: 32171632

Group type: EXPERIMENTAL
Intervention: Down syndrome (trisomy 21)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Velocardiofacial syndrome (del22q11)
Number of subjects: 0
Study: 32172456

Group type: EXPERIMENTAL
Intervention: Single-use hydrophilic-coated (HC) catheters for 4 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Single-use hydrophilic-coated (HC) catheters
Number of subjects: 39

Group type: COMPARATOR
Intervention: Reused catheters
Number of subjects: 39
Study: 32172489

Group type: EXPERIMENTAL
Intervention: BI 836826 (CD37 antibody) at doses ranging from 1 mg to 200 mg, with a maximum tolerated dose (MTD) of 100 mg; administered as an intravenous infusion once weekly for 4 weeks.
Number of subjects: 48
Study: 32172643

Group type: COMPARATOR
Intervention: Ultrasound-guided second-generation group (n=95)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided third-generation group (n=308)
Number of subjects: 403
Study: 32173192

Group type: EXPERIMENTAL
Intervention: Treatment with iliac leg endoprosthesis without coverage of the hypogastric artery
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Placement of a hypogastric branched endograft
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Hypogastric artery coverage with extension into the external iliac artery
Number of subjects: 364

Group type: COMPARATOR
Intervention: Bilateral IAAs
Number of subjects: 364

Group type: COMPARATOR
Intervention: No IAA
Number of subjects: 364
Study: 32174828

Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32174840

Group type: EXPERIMENTAL
Intervention: Salbutamol administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: No asthma treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Asthmatic children without SCD
Number of subjects: 0
Study: 32175519

Group type: EXPERIMENTAL
Intervention: small-quantity lipid-based nutrition supplement (LNS) containing >20 micronutrients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32175617

Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor T-cell therapies (CAR T-cells)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose escalation trials
Number of subjects: 0